• Shamir P Chandarana, Julia S Lee, ChanowskiEric J PEJ, Assuntina G Sacco, Carol R Bradford, Gregory T Wolf, Mark E Prince, Jeffrey S Moyer, Avraham Eisbruch, Francis P Worden, Thomas J Giordano, Bhavna Kumar, Katrina G Cordell, Thomas E Carey, and Douglas B Chepeha.
• Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada.
• Head Neck. 2013 Aug 1; 35 (8): 1083-90.

BackgroundThe purpose of this study was to describe the relationship of p16 and epidermal growth factor receptor (EGFR) expression with survival in surgically treated patients who had oropharyngeal or oral cavity squamous cell carcinoma (SCC).MethodsTissue from 36 patients with oropharyngeal SCC and 49 patients with oral cavity SCC treated between 1997 and 2001 was imbedded and immunostained using a tissue microarray.ResultsThe p16 was positive in 57% and 13% of patients with oropharyngeal SCC and oral cavity SCC, respectively. EGFR was positive in 60% and 63% of patients with oropharyngeal SCC and oral cavity SCC, respectively. In patients with oropharyngeal SCC, p16 expression was associated with improved disease-specific survival (DSS), overall survival (OS), and time to recurrence (TTR) (p < .01, < .01, and <.01, respectively). EGFR expression was associated with poorer DSS, OS, and TTR (p < .01, = .01, and < .01, respectively). For oropharyngeal SCC, when examining both p16 and EGFR expression as combined biomarkers, high p16 expression coupled with low EGFR expression was associated with improved DSS (p p16 = .01; p EGFR = .01). Patients with oral cavity SCC showed no association between biomarker and outcome.ConclusionsFor patients with oropharyngeal SCC, high p16 and low EGFR were associated with improved outcome, suggesting a predictive role in surgically treated patients.Copyright © 2012 Wiley Periodicals, Inc.

26 keywords...

hide…